News Archive

April 2019

• Press Release Apr 15, 2019

  Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

  By 2020, over 1.5 million people in the US are likely to have wet AMD, the leading cause of blindness in industrialized countries  Filing is based on Phase III data from the HAWK and HARRIER…
• Press Release Apr 15, 2019

  Europe-Africa partnership spearheads development of next-generation antimalarial drug

  The European  & Developing Countries Clinical Trials Partnership (EDCTP) grants EUR 10 million over five years to "WANECAM 2" a unique collaboration between antimalarial drug researchers in…
• In The News Apr 11, 2019

  How to be a boss in an unbossed company

  In this interview, Novartis CEO Vas Narasimhan sits down with CNNMoney Switzerland’s Urs Gredig and shares why he thinks innovation should come from the bottom and how wearing jeans and no…
• Press Release Apr 11, 2019

  Sandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countries

  Agreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…
• 
  Story Apr 09, 2019 Discovery

  Counting on combos for complex liver diseases

  The best treatment for multifaceted diseases like NASH may be combinations of drugs.

• Featured News Apr 09, 2019

  Alcon becomes a separately traded standalone company

  On April 9, 2019 Alcon becomes a separately traded company. Novartis and Alcon are now positioned to capitalize on significant growth opportunities and focus resources on their respective businesses and strategic priorities.

• Press Release Apr 09, 2019

  Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off

  Novartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
• 
  Story Apr 08, 2019 Discovery

  Bringing gene therapy into focus

  Dr. Botond Roska says we should keep our eyes on gene therapy.

• Press Release Apr 04, 2019

  Novartis updates on the migraine collaboration with Amgen

  Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
• In The News Apr 04, 2019

  Medicines and transformative effect

  In this Bloomberg interview, Vas Narasimhan, CEO of Novartis shares his thoughts on how medicines can have a transformative effect.
• Press Release Apr 03, 2019

  Sandoz resubmits biosimilar pegfilgrastim application to US FDA

  Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim  Pegfilgrastim is used to reduce the incidence of neutropenia, one…
• Featured News Apr 02, 2019

  Sustaining the momentum toward universal health coverage in Africa

  The first pan-African Novartis Social Business stakeholder dialogue took place in Kampala, Uganda, on March 20, 2019.